UCBG - Unicancer

v4 08/11/2016
French Breast Cancer Intergroupe - Unicancer
(UCBG)
ASSEMBLÉE GÉNÉRALE
-
programme
Mercredi 16 novembre de 19h00 à 21h00,
au Palais des Congrès à Dijon
(3 boulevard de Champagne - 21078 DIJON CEDEX)
Salle Santenay-Chablis
19h00-19h10 : Stratégie du groupe (S. Delaloge)
19h10-19h40 : Résultats d’études du groupe en avant-première de SABCS
ADENDOM (S. Delaloge)
UCBG 2-14: A prospective multicenter non-randomized trial evaluating the effect of
EndoPredict[reg] (EPclin[reg]) clinico-genomic test on treatment decision making among
patients with intermediate clinical risk
CARMINA02 (F. Lerebours)
Genomic analysis to evaluate response to neoadjuvant anastrozole and fulvestrant in post-
menopausal ER-positive HER2-negative breast cancer patients included in the UCBG
CARMINA02 trial
GRT02-COMET (J.Y. Pierga)
Circulating tumor cells (CTC) and endothelial cells (CEC) prognostic value in HER2 negative
metastatic breast cancer patients treated with first line weekly paclitaxel and bevacizumab:
First results of a prospective cohort from the French Breast Cancer InterGroup Unicancer
(UCBG): COMET study
19h40-20h10: Essais en phase de lancement
ULTIMATE (F. André)
A Phase II Trial Testing Durvalumab Combined With Endocrine Therapy in Patients With
ER+/Her2- Breast Cancer Eligible to Neoadjuvant Endocrine Therapy And Who Present CD8+ T
Cell Infiltration After 4-6 Weeks Exposure to Immune-Attractant
OPTIGEN (R. Rouzier)
Prospective multicenter randomized study assessing genomic test impact on shared decision of
adjuvant chemotherapy in patients with ER-positive, Her2-negative early breast cancer with
uncertainty on the indication of chemotherapy using standard assessments
PADA-1 (F.C. Bidard)
PAlbociclib and hormone therapy as first line treatment for metastatic hormone-positive HER2-
negative breast cancer: Efficacy, Safety and utility of Circulating ESR1mutation detection
20h10-20h35 : Actualité des essais en cours
RxPONDER (S. Delaloge); UNIRAD (T. Bachelot); SAFIR2 (F. André); NEOPAL (P. Cottu)
HYPOG01 (S. Rivera)
20h35-20h50 : Actualité du groupe des chirurgiens 15min (C. Coutant)
20h50 : Conclusion de la journée (S. Delaloge)
[21H00] Clôture de la séance